| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $444,169 | 2 | 100 |
Sells | $0 | 0 | 0 |
| GOWER BOB G | director | 2 | $444,169 | 0 | $0 | $444,169 |
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Over the last 12 months, insiders at Ensysce Biosciences, Inc. have bought $444,169 and sold $0 worth of Ensysce Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ensysce Biosciences, Inc. have bought $394,941 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GOWER BOB G (director) — $444,169.
The last purchase of 400,000 shares for transaction amount of $198,000 was made by GOWER BOB G (director) on 2026‑08‑07.
| 2026-08-07 | GOWER BOB G | director | 400,000 5.5652% | $0.49 | $198,000 | -23.30% | ||
| 2026-04-23 | GOWER BOB G | director | 508,614 6.2578% | $0.48 | $246,169 | -29.46% | ||
| 2023-03-02 | GOWER BOB G | director | 90,287 0.6576% | $0.49 | $44,087 | -71.07% | ||
| 2023-03-01 | GOWER BOB G | director | 270,000 2.1241% | $0.48 | $128,979 | -68.06% | ||
| 2023-02-28 | GOWER BOB G | director | 109,300 0.8628% | $0.49 | $53,371 | -68.47% | ||
| 2022-12-09 | GOWER BOB G | director | 357,143 19.2974% | $1.40 | $500,000 | -83.82% | ||
| 2022-05-25 | Kirkpatrick Lynn | Chief Executive Officer | 27,000 0.0797% | $0.53 | $14,216 | -78.38% | ||
| 2020-06-19 | Sale | MORGAN STANLEY | 10 percent owner | 776,290 0.2223% | $10.44 | $8.1M | -4.82% | |
| 2017-12-01 | HG Vora Capital Management, LLC | 10 percent owner | 1M 4.2688% | $10.00 | $10M | +28324.91% |
| GOWER BOB G | director | 916740 5.9662% | $417,758.42 | 6 | 0 | <0.0001% |
| HG Vora Capital Management, LLC | 10 percent owner | 3837500 24.9748% | $1.75M | 1 | 0 | |
| Kirkpatrick Lynn | Chief Executive Officer | 381851 2.4851% | $174,009.50 | 1 | 0 | |
| MORGAN STANLEY | 10 percent owner | 0 0% | $0 | 0 | 1 |
$6,934,920 | 41 | -9.19% | $6.83M | |
$13,664,154 | 40 | -70.35% | $6.32M | |
$29,645,465 | 28 | 8.09% | $9.84M | |
$37,200,153 | 21 | -47.67% | $7.49M | |
$287,718 | 15 | -41.45% | $8.46M | |
$11,777,042 | 10 | -11.94% | $6.57M | |
$13,595,542 | 9 | -16.74% | $7.97M | |
$108,996 | 8 | -33.42% | $6.64M | |
$192,099 | 7 | -39.17% | $5.7M | |
$40,324 | 6 | 31.82% | $5.5M | |
$76,299 | 4 | 11.60% | $7.6M | |
Ensysce Biosciences, Inc. (ENSC) | $726,438 | 4 | -72.85% | $7M |
$18,186,879 | 4 | 49.41% | $10.77M | |
$1,184,658 | 4 | -22.17% | $5.08M | |
$14,530 | 3 | 62.23% | $5.63M | |
$84,550 | 3 | 77.61% | $10.63M | |
$16,526,031 | 2 | -0.85% | $8.17M | |
$75,000 | 1 | -30.67% | $6.1M | |
$500,000 | 1 | -22.94% | $10.8M |
| Increased Positions | 12 | +75% | 206,905 | +58.83% |
| Decreased Positions | 6 | -37.5% | 55,984 | -15.92% |
| New Positions | 5 | New | 87,987 | New |
| Sold Out Positions | 5 | Sold Out | 55,284 | Sold Out |
| Total Postitions | 22 | +37.5% | 502,620 | +42.91% |
| Perceptive Advisors Llc | $81.00 | 2.17% | 86,666 | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $70.00 | 1.87% | 74,711 | 0 | 0% | 2025-09-30 |
| Drw Securities, Llc | $65.00 | 1.73% | 69,145 | +69,145 | New | 2025-09-30 |
| Vanguard Group Inc | $35.00 | 0.92% | 36,708 | +36,708 | New | 2025-09-30 |
| Renaissance Technologies Llc | $15.00 | 0.39% | 15,574 | +15,574 | New | 2025-09-30 |
| Citadel Advisors Llc | $14.00 | 0.36% | 14,518 | +14,518 | New | 2025-09-30 |
| Virtu Financial Llc | $13.00 | 0.36% | 14,222 | +14,222 | New | 2025-09-30 |
| Geode Capital Management, Llc | $12.00 | 0.33% | 13,030 | +2,869 | +28.23% | 2025-09-30 |
| Xtx Topco Ltd | $10.00 | 0.27% | 10,957 | +10,957 | New | 2025-09-30 |
| Tru Independence Asset Management 2, Llc | $10.00 | 0.26% | 10,500 | +10,500 | New | 2025-09-30 |